Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:

• Spruce Biosciences (SPRU), 21,130% surge in interest

Pipeline and key clinical candidates for these companies:

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need.

Recent news on these stocks:

October 8

Spruce Biosciences announced that it has entered into a definitive securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $50M, before deducting offering expenses, to advance tralesinidase alfa enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B through a biologics license application submission in the first quarter of 2026 and potential U.S. commercial launch in late 2026. The private placement is expected to close on or about October 9, 2025, subject to the satisfaction of customary closing conditions. Leerink Partners, Citizens Capital Markets and H.C. Wainwright & Co. are acting as placement agents for the financing and Oppenheimer & Co. is acting as capital markets advisor for the financing.

Spruce Biosciences announced that it has entered into a definitive securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $50M, before deducting offering expenses, to advance tralesinidase alfa enzyme replacement therapy for the treatment of Sanfilippo Syndrome Type B through a biologics license application submission in the first quarter of 2026 and potential U.S. commercial launch in late 2026. The private placement is expected to close on or about October 9, subject to the satisfaction of customary closing conditions. Under the securities purchase agreement, the investors have agreed to purchase approximately 502,181 shares of the company’s common stock at a purchase price of $68.00 per share. In lieu of shares of common stock, as a portion of their investment, certain investors are purchasing pre-funded warrants to purchase up to 233,144 shares of common stock at a purchase price of $67.99, which equals the purchase price per share of common stock, less the $0.01 per share exercise price of each pre-funded warrant. The pre-funded warrants will be exercisable for a period of five years following the date of issuance. Leerink Partners, Citizens Capital Markets and H.C. Wainwright & Co. are acting as placement agents for the financing and Oppenheimer & Co. is acting as capital markets advisor for the financing.

Hear more from InvestingChannel by signing up for The Spill.

About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.